TRIM46 and triple-negative breast carcinoma: In the CNA landscape of early triple-negative breast cancer (eTNBC) population, TRIM46 (10.8%) dominates as a focal amplification alteration, while PTEN (5.4%) dominates as a homozygous deletion (Supplementary Fig. S1B).